Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

ADMP has been the subject of several other reports. Maxim Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of Adamis Pharmaceuticals Corporation in a research report on Monday, June 12th. Zacks Investment Research raised shares of Adamis Pharmaceuticals Corporation from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Tuesday, February 21st.

Adamis Pharmaceuticals Corporation (ADMP) opened at 5.10 on Friday. The firm’s market cap is $140.57 million. The company has a 50-day moving average of $4.04 and a 200 day moving average of $3.72. Adamis Pharmaceuticals Corporation has a 12-month low of $2.40 and a 12-month high of $6.45.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/06/20/adamis-pharmaceuticals-corporation-admp-stock-rating-upgraded-by-valuengine.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley raised its position in shares of Adamis Pharmaceuticals Corporation by 8.8% in the first quarter. Morgan Stanley now owns 25,781 shares of the specialty pharmaceutical company’s stock valued at $110,000 after buying an additional 2,075 shares during the last quarter. Axiom International Investors LLC DE acquired a new position in shares of Adamis Pharmaceuticals Corporation during the first quarter valued at about $1,698,000. Geode Capital Management LLC raised its position in shares of Adamis Pharmaceuticals Corporation by 43.2% in the first quarter. Geode Capital Management LLC now owns 85,464 shares of the specialty pharmaceutical company’s stock valued at $363,000 after buying an additional 25,770 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Adamis Pharmaceuticals Corporation by 12.9% in the first quarter. Vanguard Group Inc. now owns 771,773 shares of the specialty pharmaceutical company’s stock valued at $3,280,000 after buying an additional 87,974 shares during the last quarter. Finally, Sterling Global Strategies LLC raised its position in shares of Adamis Pharmaceuticals Corporation by 6.5% in the first quarter. Sterling Global Strategies LLC now owns 42,600 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 2,600 shares during the last quarter. Institutional investors own 11.29% of the company’s stock.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.